Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Feb 11, 2019 3:12pm
83 Views
Post# 29348698

RE:RE:RE:RE:RE:RE:RE:RE:RE:Sales Revenue (4147 TMB) January 2019

RE:RE:RE:RE:RE:RE:RE:RE:RE:Sales Revenue (4147 TMB) January 2019
SPCEO1 wrote:
palinc2000 wrote:
SPCEO1 wrote:
PoorOpinion wrote:
SPCEO1 wrote:
palinc2000 wrote:
SPCEO1 wrote: The Bloomberg data is the best source of data now and it is showing improvement, with last week's number being the highest yet by a nice margin. The Taimed sales number is impacted by inventory changes at TH.
Dwizell wrote:
Garp1 wrote:
38,939


This is very bad as we don’t have the J code excuses for this 4 th near flat month in a row ...

 


Do you know for a fact that inventories held at TH  have decreased ?
Why would they decrease inventories when sales are supposedly increasing?
 


No, but it has to be the case since Trogarzo sales are rising at the TH level (according to Bloomberg, which has its problems but is generally accurate). Since TH can't sell what it does not have and its sales of Trogarzo are rising, that means they have to be working down invetories of Trogarzo if Taimed's Trogarzo sales to TH are flattish.  


The thing is if sales were improving in a substantial way then you would expect BOTH numbers to increase. Especially given that early in the process thera said they didnt actually hold much stock and the increases in taimed sales in the few months were they increased (i think the best month was 510000) were quite limited. There really isnt a great deal of spare inventory in the system. As others have said there is a limited life to this explanation and it seems we've come to the end of it.

SPCEO any chance you could give us the last weeks actual bloomberg sales. Is it vials sold? The actual number of vials? Or maybe 4 week moving average?
 


It seems many here are getting hung up on the Taimed sales and that is just creating unnecessary confusion. You can ignore Taimed sales for now as it only represents the amount that Taimed sells to TH and what matters to us is the amount TH sells to its distributor. Those numbers will be comparable at some point in the future but for the moment, the Taimed sales to TH are just not giving you an accurate picture of Trogarzo sales. So, if you are all twisted up by those Taimed sales numbers, you have my permission to just stop fussing aboutthem and ignore the for now.  

TH has said the total quantity of vials sold as reported by Bloomberg is the best approximation of actual sales and it continues to grow. If you use the last data point on Bloomberg, it suggests 333 patients (using 8.5 doses per patient per month - some are getting the heavier loading dose each month and some months are longer than the 4 week cycle I am assuming). That 333 likely overstates reality since it is using the latest data point which was the best ever by a nice amount. But if sales keep growing as they have recently, it will not be very long at all long before that number is too low an estimate of the numebr of patients.    

Also, we probably should assume that Bloomberg has not captured every prescription written for Trogarzo. So, 333 might be very close to the current number of patients taking that into consideration.

333 patients now would mean 233 new patients since the third week of May 2018 when  according to Luc the first 100 patients had been reached .So the first 3 weeks in May we had 33 new patients PER WEEK  and since then ONLY about 25 patients PER MONTH....


 


Which is why we are dissapointed in Trogarzo. But there is no guarantee this trend will continue at that rate. It could go higher or lower as well. We will hopefully get a good idea in the next few months or so if they can get the sales trend kicked into a higher gear or not. At the moment, it looks like it is moving into a new higher gear but we will need some more data points to prove that to be the case. 


To give SPCEO (the cheerleader) a break for the moment ;)

I think in the last cc they did talk about the time delay between writing scripts and getting them filled. My memory is its down to about 30days???? So if the new year (and new J-codes) was an inflection point then we probably wouldnt be seeing that reflected in the bloomberg data until last week (assuming bloomberg is filled scripts).
Bullboard Posts